跳至主要内容
临床试验/NCT06260878
NCT06260878招募中4 期

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis

University of Calgary2 个研究点 分布在 1 个国家目标入组 505 人开始时间: 2024年11月22日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
505
试验地点
2
主要终点
Serum amylase

研究概览

简要总结

This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age 18-75 years (due to higher likelihood of undiagnosed cardiac disease or renal insufficiency in patients >75 years of age)
  • ability to give informed consent
  • native major papillary anatomy
  • ability and willingness to obtain bloodwork the day after ERCP

排除标准

  • prior ERCP with sphincterotomy and/or sphincteroplasty
  • confirmed or suspected cholangitis or sepsis
  • confirmed pancreatitis, hyperlipasemia, or hyperamylasemia within the preceding 7 days
  • NYHA Class II or greater heart failure
  • active pulmonary edema
  • myocardial infarction or ischemia within the preceding 3 months
  • renal insufficiency with CrCl < 40 mL/minute
  • CPT Class B or C cirrhosis and/or end-stage liver disease
  • room air oxygen saturation <90% or requirement of home O2
  • hypernatremia with Na+ ≥ 150 mEq/L or Na+ <130 mEq/L
  • uncontrolled hypertension or hypotension
  • pregnant status

结局指标

主要结局

Serum amylase

时间窗: 24 hours

次要结局

  • Cholangitis(14 days)
  • Brain natriuretic peptide(24 hours)
  • Cardiorespiratory adverse event(7 days)
  • Serum lipase(24 hours)
  • Creatinine(24 hours)
  • Pancreatitis(7 days)
  • Bleeding(30 days)
  • Electrolytes(24 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验